Literature DB >> 28137859

Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.

Wenbo Wu1,2, Zhiwei Lu2, Fei Li2, Wenjie Wang2, Nannan Qian2, Jinzhi Duan2, Yu Zhang2, Fengchao Wang2, Ting Chen3.   

Abstract

The prokaryotic CRISPR/Cas9 system has recently emerged as a powerful tool for genome editing in mammalian cells with the potential to bring curative therapies to patients with genetic diseases. However, efficient in vivo delivery of this genome editing machinery and indeed the very feasibility of using these techniques in vivo remain challenging for most tissue types. Here, we show that nonreplicable Cas9/sgRNA ribonucleoproteins can be used to correct genetic defects in skin stem cells of postnatal recessive dystrophic epidermolysis bullosa (RDEB) mice. We developed a method to locally deliver Cas9/sgRNA ribonucleoproteins into the skin of postnatal mice. This method results in rapid gene editing in epidermal stem cells. Using this method, we show that Cas9/sgRNA ribonucleoproteins efficiently excise exon80, which covers the point mutation in our RDEB mouse model, and thus restores the correct localization of the collagen VII protein in vivo. The skin blistering phenotype is also significantly ameliorated after treatment. This study provides an in vivo gene correction strategy using ribonucleoproteins as curative treatment for genetic diseases in skin and potentially in other somatic tissues.

Entities:  

Keywords:  Cas9/sgRNA ribonucleoproteins; RDEB; electroporation; in vivo gene editing; skin stem cell

Mesh:

Substances:

Year:  2017        PMID: 28137859      PMCID: PMC5321012          DOI: 10.1073/pnas.1614775114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

Review 3.  Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Maija Kiuru; Munenari Itoh; Mitchell S Cairo; Angela M Christiano
Journal:  Dermatol Clin       Date:  2010-04       Impact factor: 3.478

4.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

5.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

6.  Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.

Authors:  Mei Chen; Noriyuki Kasahara; Douglas R Keene; Lawrence Chan; Warren K Hoeffler; Deborah Finlay; Maria Barcova; Paula M Cannon; Constance Mazurek; David T Woodley
Journal:  Nat Genet       Date:  2002-11-11       Impact factor: 38.330

7.  Stable nonviral genetic correction of inherited human skin disease.

Authors:  Susana Ortiz-Urda; Bhaskar Thyagarajan; Douglas R Keene; Qun Lin; Min Fang; Michele P Calos; Paul A Khavari
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

8.  Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

9.  Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa.

Authors:  David T Woodley; Douglas R Keene; Tom Atha; Yi Huang; Kathi Lipman; Wei Li; Mei Chen
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

10.  Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.

Authors:  David T Woodley; Gerald G Krueger; Cynthia M Jorgensen; Janet A Fairley; Tom Atha; Yi Huang; Lawrence Chan; Douglas R Keene; Mei Chen
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

View more
  31 in total

1.  Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.

Authors:  Moira A McMahon; Thazha P Prakash; Don W Cleveland; C Frank Bennett; Meghdad Rahdar
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 2.  Genome editing for the reproduction and remedy of human diseases in mice.

Authors:  Satoshi Hara; Shuji Takada
Journal:  J Hum Genet       Date:  2017-11-27       Impact factor: 3.172

3.  CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (Nrip1) in adipose cells to enhance energy expenditure.

Authors:  Yuefei Shen; Jessica L Cohen; Sarah M Nicoloro; Mark Kelly; Batuhan Yenilmez; Felipe Henriques; Emmanouela Tsagkaraki; Yvonne J K Edwards; Xiaodi Hu; Randall H Friedline; Jason K Kim; Michael P Czech
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

Review 4.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 5.  Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer.

Authors:  Jingyue Yan; Diana D Kang; Gillian Turnbull; Yizhou Dong
Journal:  Adv Drug Deliv Rev       Date:  2021-11-09       Impact factor: 15.470

Review 6.  The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.

Authors:  Ross C Wilson; Luke A Gilbert
Journal:  ACS Chem Biol       Date:  2017-10-19       Impact factor: 5.100

Review 7.  Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.

Authors:  Alesya G Bykonya; Alexander V Lavrov; Svetlana A Smirnikhina
Journal:  Mol Biotechnol       Date:  2022-03-24       Impact factor: 2.695

Review 8.  Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects.

Authors:  I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov
Journal:  Bull Exp Biol Med       Date:  2021-05-29       Impact factor: 0.804

Review 9.  Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy.

Authors:  M Alejandra Zeballos C; Thomas Gaj
Journal:  Trends Biotechnol       Date:  2021-07       Impact factor: 21.942

10.  COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Stefan Hainzl; Patricia Peking; Thomas Kocher; Eva M Murauer; Fernando Larcher; Marcela Del Rio; Blanca Duarte; Markus Steiner; Alfred Klausegger; Johann W Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-07-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.